EGFR and non-small cell lung carcinoma: From the efficacy analysis of current study with limited number of patients, we concluded that PIK3CA mutation may play some role in affecting the EGFR‐TKI efficacy and is a potential indicator of mTOR inhibitor treatment in NSCLC, but needs to be validated with a large number of patients.